Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 12/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GUSB | P08236 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12667078 | 0.88 | TRPV1 (0.41) | TRPV1AKR1C3AKR1C2GAKIDO1 | |
| SCHEMBL1862905 | 0.86 | TRPV1 (0.45) | TRPV1AKR1C3AKR1C2GAKSORT1 | |
| SCHEMBL1860683 | 0.85 | TRPV1 (0.68) | TRPV1MAPK3 | |
| SCHEMBL1859532 | 0.83 | TRPV1 (0.51) | TRPV1AKR1C3AKR1C2MAPK3NPC1 | |
| SCHEMBL1859921 | 0.83 | TRPV1 (0.48) | TRPV1GAKNPC1GUSBMAPT | |
| SCHEMBL4355548 | 0.80 | TRPV1 (0.76) | TRPV1MAPK3 | |
| SCHEMBL1865465 | 0.77 | TRPV1 (0.65) | TRPV1MAPK3 | |
| SCHEMBL1869242 | 0.77 | TRPV1 (0.53) | TRPV1MAPK3NPC1 | |
| SCHEMBL1860183 | 0.77 | TRPV1 (0.44) | TRPV1MAPK3SORT1 | |
| SCHEMBL1862355 | 0.76 | MRGPRX4 (0.40) | TRPV1AKR1C3AKR1C2IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935702-B2 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2011-05-03 | — | — | US | disclosed |
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111337-A1 | Substituted biaryl quinolin-4-ylamine analogues | PIGS, GPR52, GPR174 | TRPV1 549/4885AKR1C3 799/4885AKR1C2 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.